Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline

Journal of Chemotherapy

Volumn 17, Issue SUPPL. 1, 2005, Pages 12-22

  Rello, J ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Pharmacokinetics tigecycline; Safety tigecycline; Tigecycline

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTACID AGENT; ANTIDIARRHEAL AGENT; ASPARTATE AMINOTRANSFERASE; AZTREONAM; BICARBONATE; BISMUTH SALICYLATE; CALCIUM; CILASTATIN; DIGOXIN; DIURETIC AGENT; IMIPENEM; INSULIN; KAOLIN; LAXATIVE; MAGNESIUM SALICYLATE; METHOXYFLURANE; MULTIVITAMIN; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PECTIN; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; AGE; ANOREXIA; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ASIAN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CAUCASIAN; CHINESE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FOOD DRUG INTERACTION; GENDER; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; INJECTION SITE REACTION; KIDNEY DISEASE; KLEBSIELLA PNEUMONIAE; LACTATION; LIVER DYSFUNCTION; MAXIMUM TOLERATED DOSE; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEISSERIA GONORRHOEAE; OBESITY; PHARMACODYNAMICS; PREGNANCY; PRURITUS; RACE; RASH; REVIEW; SINGLE DRUG DOSE; SKIN INFECTION; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TERATOGENICITY; URTICARIA; VOLUNTEER; VOMITING;

EID: 28044443844     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.supplement-1.12     Document Type: Review

References (31)

1. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64(1): 63-88.
2. Muralidharan G, Micalizzi M, Speth J, Raible DG, Troy SM. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother, 2005; 49(1): 220-229.
3. Tombs NL. Tissue distribution of Gar-936, a broad-spectrum antibiotic, in male rats. Abstr. 39th Intersci. Conf. Antimicrob Agents Chemother 1999; 39(302): 26.
4. Sun HK, Ong AUCT, Harper D, Troy S, Nightingale CH, Nicolau DP. Pharmacokinetic profile of tigecycline in serum and blister fluid after multiple intravenous administrations in healthy adults. In ICAAC 2004. October 30-November 2, 2004, Washington DC.
5. Conte JE, Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25(6): 523-529.
6. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males (abstract number A-1403). Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother, 2002. 42: 22.
7. MacDonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther, 1973; 14(5): 852-61.
8. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sept, 2003: 5.
9. Saunders S, Baird-Bellaire SJ, Patat AA et al. Pharmacokinetics (PK) of tigecycline (TGC) in patients with hepatic impairment. In European Association for Clinical Pharmacology and Therapeutics (EACPT). 2005. Poznan, Poland. Abstract 001777.
10. Muralidharan G, Mojaverian P, Micalizzi M, et al. The effects of age and gender on the pharmacokinetics, safety and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. In Interscience Conference on Antimicrobial Agents & Chemotherapy 2000; 518: 17.
11. Passarell JA, Meagher A, Liolios KA, et al. Pharmacokinetic/ pharmacodynamic model of the tolerability of tigecycline in healthy volunteers. In European Congress of Clinical Microbiology and Infectious Diseases. 2005. Copenhagen, Denmark: Clin Microbiol Infect. Poster P894.
12. Jiang J, Liu Z, Fan H, et al. An ascending single dose study evaluating the safety, tolerability and pharmacokinetics (PK) of tigecycline in healthy Chinese men. In International Symposium on Antimicrobial Agents and Resistance (ISAAR). 2005. Abstract NA24.
13. Data on File, Wyeth Investigator's Brochure Tigecycline (GAR-936) [WAY-156936]. 2004, Wyeth Clinical Research and Development Department, p. 288
14. Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DJ, Fruncillo RJ. Tigecycline (TGC) and digoxin(DIG) co-administered to healthy men. In ICAAC 2004. 2004. October 30-November 2, 2004, Washington DC. Abstract A-460.
15. Raible D, Zimmerman JJ, Harper D, Speth J. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin co-administered to healthy subjects. In press, 2005.
16. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46(8): 2595-601.
17. Hoellman DB, Pankuch GA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of GAR 936, a new glycylcycline, compared to those of nine other agents against penicillin susceptible and resistant pneumococci. Antimicrob Agents Chemother 2000; 44(4): 1085-8.
18. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48(11): 4479-4481.
19. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47(1): 216-222.
20. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44(11): 3022-3027.
21. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44(4): 943-949.
22. Petersen PJ, Weiss WJ, Labthavikul P, Bradford PA. The post-antibiotic effect and time-kill kinetics of the glycylcyclines, GAR-936 (TBG-MINO) and (PAM-MINO). Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. 38(266): 24.
23. Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003; 47(2): 529-532.
24. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47(2): 533-540.
25. Postier R, Klein S, Green S, Loh E. Results of a phase 2, open-label, safety, and efficacy study of tigecycline to treat complicated skin and skin structure infections in hospitalized patients. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., 2003; 43: 416.
26. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., 2003; 43: 416.
27. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase III comparison study with vancomycin/aztroenam. Antimicrob Agents Chemother, 2005, in press.
28. Sacchidanand S, Penn RL, Embil J, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3 randomised double-blind trial. Int J Infect Dis, 2005: in press.
29. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg, 2005: in press.
30. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis, 2005, in press.
31. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E and Tigecycline-200 StudyGroup. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther, 2004; 26(5): 704-714.